Bliss GVS Pharma Cash flow Statement
Figures in Cr
Consolidated Cash Flow Results
Mar'26
Mar'25
Mar'24
Mar'23
Mar'22
Mar'21
No of Months
12
12
12
12
12
12
Profit Before Tax
189.00
125.00
146.00
106.00
127.00
104.00
Adjustment
95.00
68.00
38.00
57.00
-31.00
46.00
Changes In working Capital
-104.00
-51.00
-46.00
-85.00
73.00
-57.00
Cash Flow after changes in Working Capital
181.00
142.00
137.00
78.00
169.00
92.00
Cash Flow from Operating Activities
138.00
105.00
102.00
34.00
135.00
63.00
Cash Flow from Investing Activities
-38.00
-75.00
-83.00
-6.00
-102.00
-45.00
Cash Flow from Financing Activities
-89.00
-30.00
-20.00
-24.00
-23.00
-20.00
Net Cash Inflow / Outflow
11.00
0.00
-1.00
3.00
8.00
-2.00
Opening Cash & Cash Equivalents
23.00
23.00
25.00
21.00
13.00
15.00
Cash & Cash Equivalent on Amalgamation / Take over / Merger
0.00
0.00
0.00
0.00
0.00
0.00
Cash & Cash Equivalent of Subsidiaries under liquidations
0.00
0.00
0.00
0.00
0.00
0.00
Translation adjustment on reserves / op cash balances foreign subsidiaries
0.00
0.00
0.00
0.00
0.00
0.00
Effect of Foreign Exchange Fluctuations
0.00
0.00
0.00
0.00
0.00
0.00
Closing Cash & Cash Equivalent
35.00
23.00
23.00
25.00
21.00
13.00
Figures in INR Cr
Seasonal companies are compared with the same quarter last year
Seasonal companies are compared with the same quarter last year
Compare Cash Flow Results of Bliss GVS Pharma
Figures in Cr
consolidated Cash Flow Results
Change(INR)
Change(%)
Profit Before Tax
189.59
188.26
1.00
0.71%
Adjustment
95.87
57.64
38.00
66.33%
Changes In working Capital
-104.45
-103.13
-1.00
-1.28%
Cash Flow after changes in Working Capital
181.01
142.77
39.00
26.78%
Cash Flow from Operating Activities
138.72
116.52
22.00
19.05%
Cash Flow from Investing Activities
-38.18
-107.12
69.00
64.36%
Cash Flow from Financing Activities
-89.21
-21.72
-68.00
-310.73%
Net Cash Inflow / Outflow
11.32
-12.32
23.00
191.88%
Opening Cash & Cash Equivalents
23.82
15.52
8.00
53.48%
Cash & Cash Equivalent on Amalgamation / Take over / Merger
0
0
0.00
0.00%
Cash & Cash Equivalent of Subsidiaries under liquidations
0
0
0.00
0.00%
Translation adjustment on reserves / op cash balances foreign subsidiaries
0
0
0.00
0.00%
Effect of Foreign Exchange Fluctuations
0
0
0.00
0.00%
Closing Cash & Cash Equivalent
35.14
3.2
32.00
998.12%
Cash Flow - Snapshot (Consolidated) - Mar'26
YoY Growth in year ended Mar 2026 is 30.98% vs 3.01% in Mar 2025
Mar'26
Mar'25
Change(%)
Cash Flow from Operating Activities
138.72
105.91
30.98%






